Novo Nordisk and Eli Lilly announced a partnership with telehealth platform Mangoceuticals to distribute their GLP‑1 weight‑loss drugs Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) through the company’s digital pharmacy and prescription services. The collaboration will allow patients to receive virtual consultations, personalized treatment plans, and medication fulfillment via partner or local pharmacies, creating a seamless ordering and delivery experience for users of the two blockbuster drugs.
The announcement comes on the heels of strong Q3 2025 earnings for both pharmaceutical giants. Eli Lilly reported revenue of $17.60 billion, up 54% year‑over‑year, and a non‑GAAP EPS of $7.02, beating analyst expectations by $0.24. The growth was driven by robust demand for Mounjaro and Zepbound, prompting the company to raise its full‑year revenue guidance. Novo Nordisk posted Q3 revenue of DKK 74.98 billion (≈$9.6 billion), a 5.2% increase, while net profit fell 27% but adjusted net profit rose 5%. The company’s guidance was tightened to a 8‑11% sales growth range, reflecting a cautious outlook for its GLP‑1 portfolio.
Mangoceuticals, a small‑cap telehealth firm focused on men’s and women’s wellness, has faced financial challenges, reporting low revenue growth and substantial losses. The partnership provides the company with access to high‑margin, high‑demand GLP‑1 drugs, potentially transforming its revenue mix and strengthening its competitive position in the rapidly expanding weight‑loss market.
The partnership leverages Mangoceuticals’ existing membership model—$99 per month for unlimited telehealth visits, progress tracking, and lifestyle coaching—while the GLP‑1 medications are supplied separately. Patients can schedule virtual appointments, receive prescriptions, and have the drugs delivered through the platform’s network of partner pharmacies, thereby bypassing traditional pharmacy networks and accelerating patient access.
The deal is strategically significant amid a GLP‑1 market projected to reach hundreds of billions of dollars by 2030. Novo Nordisk and Eli Lilly have historically dominated the segment, with Wegovy and Mounjaro/Zepbound capturing the largest shares. By expanding distribution through telehealth, the companies aim to capture a larger share of the market, compete more effectively against other GLP‑1 providers, and meet the growing demand for self‑pay and uninsured patients.
Investors reacted positively to the announcement, with the partnership seen as a win for Mangoceuticals and a reinforcement of the pharma firms’ telehealth strategy. The collaboration aligns with broader industry trends of leveraging digital platforms to improve patient access to high‑cost medications and supports White House initiatives to reduce GLP‑1 medication costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.